Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2566 • ACR Convergence 2023
Comparisons of the Risk of Serious Infections Associated with the Different Classes of Targeted Therapies Used in Psoriatic Arthritis Patients: A Nationwide Cohort Study from the French Health Insurance Database
Léa Bastard¹, pascal claudepierre², Laetitia Penso³, Emilie Sbidian⁴ and Laura PINA VEGAS⁵, ¹Henri Mondor University Hospital (APHP) / Rheumatology Department, Créteil, France, ²Universitary Henri Mondor Hospital, Creteil, France, ³Université Paris Est Créteil, Créteil, France, ⁴Hôpital Henri Mondor, Université Paris Est Créteil, Créteil, France, ⁵Henri Mondor University Hospital (APHP), Rheumatology Department, Créteil, France
Background/Purpose: Targeted therapies have demonstrated their efficacy in the treatment of psoriatic arthritis (PsA), with an increased risk of serious infections. However, a comparison of…
Abstract Number: 0484 • ACR Convergence 2023
Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis: A Prospective Cohort Study
Lihi Eder¹, Vinod Chandran², Cheryl Rosen³, Richard J. Cook⁴ and Dafna Gladman⁵, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Division of Dermatology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Simple and accessible biomarkers that predict the development of psoriatic arthritis (PsA) among psoriasis patients are critically needed to improve early detection of high-risk…
Abstract Number: 0500 • ACR Convergence 2023
Analysis of the Probability of Retention of Golimumab as a Two-phase Exponential Decay Curve in Rheumatoid Arthritis or Spondyloarthropathies to Identify Patients with Higher Probability of Long-term Retention
Jose Federico Diaz-Gonzalez¹, Luis Cea-Calvo², Enrique González-Dávila³, Marta Sánchez-Jareño², Manuel Enrique Pombo Suarez⁴, Fernando Alonso⁵ and Isabel Castrejon⁶, ¹Hospital Universitario de Canarias, La Laguna, Spain, ²Medical Affairs, MSD Spain, Madrid, Spain, ³Department of Mathematics, Statistics and Operation Reseach La Laguna University, La Laguna, Spain, ⁴Hospital Clínico Universitario, Santiago de Compostela, Spain, ⁵Spanish Society of Rheumatology, Madrid, Spain, ⁶Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Selecting patients with the highest probability of long-term retention of biological treatments is important from a clinical and cost-effectiveness point of view. In this…
Abstract Number: 0775 • ACR Convergence 2023
Effectiveness of Dose Reduction and Withdrawal Strategies of TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: Long Term Extension of the DRESS-PS Study
Amy Peeters, C.A.J Michielsens, Elien Mahler, Lise Verhoef, Alfons den Broeder, Nathan den Broeder and Noortje van Herwaarden, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are effective in PsA and axial SpA, but are associated with increased infections risk, patient burden and high costs.…
Abstract Number: 1346 • ACR Convergence 2023
Semen Analysis of Patients with Psoriatic Arthritis, Axial Spondyloarthritis and Healthy Controls
Katya Meridor¹, Shimi Barda², Ofir Elalouf², Victoria Furer², Sara Pel³, Hila Nochomovitz⁴, michael zisapel², Jonathan Wollman², Reut Tzemach², Mark Berman⁵, Sara Borok⁶, Hagit Sarbagil-Maman⁷, Hagit Padova⁸, David levartovsky², Tzippy Shochat⁹, Daphna Paran², Ron Hauser², Ori Elkayam² and Ari Polachek⁶, ¹Tel Aviv Medical Center, Kfar Saba, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Tel Aviv Medical Center, Modiin, Israel, ⁴Ichilov, Tel Aviv, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁶Sourasky Medical Center, Tel Aviv, Israel, ⁷Tel Aviv Sourasky Medical center, Kiryat Ono, Israel, ⁸Tel Aviv Medical center, Petah-Tikva, Israel, ⁹Rabin Medical Center, Modiin, Israel
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are commonly diagnosed in young males in their reproductive years. However, only a few studies have investigated…
Abstract Number: 1423 • ACR Convergence 2023
Impact of Upadacitinib on Enthesitis and Dactylitis by Location in Patients with Psoriatic Arthritis and an Inadequate Response to Biologic DMARDs from the SELECT-PsA 2 Trial
Laura Coates¹, Catherine Bakewell², Majed Khraishi³, Shirley Chen⁴, Tianming Gao⁴, Arathi Setty⁴, Heather Jones⁵, Sandra Ciecinski⁴ and Eduardo Mysler⁶, ¹University of Oxford, Oxford, United Kingdom, ²Intermountain Healthcare Medical Group, Salt Lake City, UT, ³Memorial University of Newfoundland, St. John's, NL, Canada, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Mettawa, IL, ⁶Organización Medica de Investigación, Buenos Aires, Argentina
Background/Purpose: Enthesitis and dactylitis are associated with reduced quality of life and greater impairment in daily activities. In the SELECT-PsA 2 phase 3 trial, the…
Abstract Number: 1439 • ACR Convergence 2023
Better Drug Retention on anti-IL17A Compared to Anti-TNF Therapy Despite Its Inferior Effect on Composite Joint Indexes and Quality of Life in Patients with PsA–analysis from the Czech Biologics Registry ATTRA
Jakub Zavada¹, Jana Baranová², Karel Pavelka³, Jiri Vencovsky⁴, Pavel Horak⁵, Lenka Klementová⁶ and Ladislav Senolt⁷, ¹Institute of Rheumatology; Charles University, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Brno, Czech Republic, ³Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁴Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Department of Internal Medicine III- Nephrology, Rheumatology, Endocrinology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic, ⁶Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: To compare drug survival, effectiveness and safety of anti-IL17A with anti-TNF drugs as first line biologic therapy in patients (pts) with PsA using real…
Abstract Number: 1757 • ACR Convergence 2023
Quantitative Assessment of Synovial Vascularity Using Power Doppler Index in Rheumatoid Arthritis and Psoriatic Arthritis Patients with High Disease Activity
Michał Jakubaszek, Maria Maślińska and Brygida Kwiatkowska, National Institute of Geriatrics Rheumatology and Rehabilitation, Warsaw, Poland
Background/Purpose: Usefulness of quantitative assessment of synovial vascularity in ultrasound (US) imaging in patients with active RA and PsA (peripheral arthritis). Additionally the assessment of…
Abstract Number: 2229 • ACR Convergence 2023
Individual Entheseal Points Have Differential Frequency of Involvement and Impact on Patient Reported Outcomes in Patients with Active Psoriatic Arthritis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies
Laura Coates¹, Iain McInnes², Sibel Aydin³, Mitsumasa Kishimoto⁴, Philip J. Mease⁵, May Shawi⁶, Miriam Zimmermann⁷, Emmanouil Rampakakis⁸, Frederic Lavie⁹ and Dennis McGonagle¹⁰, ¹University of Oxford, Oxford, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³Department of Medicine, Ottawa Hospital Riverside Campus, Ottawa, ON, Canada, ⁴Kyorin University School of Medicine, Yokohoma, Japan, ⁵Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁶Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁷Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland, ⁸McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ¹⁰Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: In patients with mono/oligoarticular psoriatic arthritis (PsA), swelling or tenderness of specific joints can be associated with poorer patient-reported outcomes (PROs) and physician global…
Abstract Number: 2245 • ACR Convergence 2023
Drug Survival of Risankizumab vs Other Biologics After 13 Months of Treatment Among Patients with PsA in the Multicountry Postmarketing Observational VALUE Study
Lars Erik¹, Kim A Papp², Andrew Östör³, Vassilis Stakias⁴, Tshepiso Madihlaba⁴, Ralph Lippe⁵, Ran Liu⁴ and Diamant Thaçi⁶, ¹Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ²Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada, ³Monash University & Emeritus Research; Australian National University, Melbourne, Australia, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁶Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany
Background/Purpose: Risankizumab (RZB) is an optimized IL-23 inhibitor (IL-23i) currently approved for the treatment of plaque psoriasis (PsO), PsA, and Crohn's disease. In a post…
Abstract Number: 2567 • ACR Convergence 2023
An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Christoph Berger², Christos Polysopoulos¹, Adrian Ciurea³, Diego Andrey⁴, Tanja Maletic¹, Myriam Riek¹, Almut Scherer¹, Isabell von Loga¹, Judith Safford¹, Kim Lauper⁵, Burkhard Moeller⁶, Nicolas Vuilleumier⁴, Axel Finckh⁷ and Andrea Rubbert-Roth⁸, ¹SCQM Foundation, Zurich, Switzerland, ²University Hospital Basel, Basel, Switzerland, ³University Hospital Zurich, Zürich, Switzerland, ⁴Geneva University Hospitals, Geneva, Switzerland, ⁵Geneva University Hospitals, Genève, Switzerland, ⁶Inselspital - University Hospital Bern, Bern, Switzerland, ⁷HUG, Geneva, Switzerland, ⁸Cantonal Hospital St. Gallen, St. Gallen, Switzerland
Background/Purpose: There is evidence that extending the interval between COVID-19 vaccination doses is associated with increased immunogenicity and neutralizing activity in healthy individuals (1, 2).…
Abstract Number: 0485 • ACR Convergence 2023
Sex and Treatment-associated Outcomes in Patients with Active Psoriatic Arthritis Treated with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial
Lihi Eder¹, Alexis R Ogdie², Subhashis Banerjee³, Miroslawa Nowak³, Thomas Lehman⁴ and Philip J. Mease⁵, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²University of Pennsylvania, Philadelphia, PA, ³Bristol Myers Squibb, Princeton, NJ, ⁴Bristol Myers Squibb, Philadelphia, PA, ⁵Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Sex differences have been reported in pathophysiology, clinical manifestations, and treatment responses in several rheumatic diseases, including psoriatic arthritis (PsA).1 Although PsA is equally…
Abstract Number: 0501 • ACR Convergence 2023
Multicentre Study of Uveitis in Spondyloarthritis: Prevalence, Characteristics, and Prognosis
Nikolaos Kougkas¹, Konstantina Magiouf², Chrysoula Gialouri³, Gerasimos Evangelatos⁴, Maria Pappa², Afroditi Mpitouli⁵, Alexios Iliopoulos⁶, Theodoros Dimitroulas⁷, Anastasios Karamanakos⁸, Aikaterini Dimouli⁸, Maria Tektonidou², Petros Sfikakis⁹ and George Fragoulis¹⁰, ¹4th Internal Department, Ippokratio Hospital, Aristotle University of Thesaaloniki, Thessaloniki, Greece, ²Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³National and Kapodistrian University of Athens, Zografou, Greece, ⁴Rheumatology Department, 417 Army Share Found Hospital (NIMTS), Athens, Greece, ⁵Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, ⁶NIMTS Veterans Hospital, Zografou, Greece, ⁷Aristotle University of Thessaloniki - School of Medicine, Thessaloniki, Greece, ⁸“Evangelismos” General Hospital, Rheumatology Department, Athens, Greece, ⁹National Kapodistrian University of Athens Medical School, Athens, Greece, ¹⁰"Laiko" Hospital - First Department of Propaedeutic and Internal Medicine, Athens, Greece
Background/Purpose: Data are still scarce about risk factors predicting the occurrence and course of uveitis in spondyloarthritis (SpA). We aimed to examine associations between demographic,…
Abstract Number: 0776 • ACR Convergence 2023
Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: 16- and 52-Week Results from a Randomized, Double-Blind, Phase 3 Study
Alan Kivitz¹, Liliana Sedova², Melvin Churchill³, Roshan Kotha⁴, Atul Singhal⁵, Alexander Torres⁶, Guillermo Valenzuela⁷, Sarah Whelan⁸, Thomas Dumortier⁹, Xuan Zhu¹⁰, Ruvie Martin¹⁰ and Luminita Pricop¹⁰, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Institute of Rheumatology, Prague, Czech Republic, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Sharp Community Medical Group, La Mesa, CA, ⁵Southwest Arthritis Research Group, Mesquite, TX, ⁶Highlands Advanced Rheumatology and Arthritis Center, Avon Park, FL, ⁷Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁸Novartis Ireland Ltd, Dublin, Ireland, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: To investigate the long-term efficacy, safety, and tolerability of intravenous (IV) secukinumab (SEC) in patients with active psoriatic arthritis (PsA) through 52 weeks.Methods: INVIGORATE-2…
Abstract Number: 1349 • ACR Convergence 2023
Paternal Effects of Anti-TNFs in Inflammatory Arthritis
Zeynep Toker Dincer, Bahaddin Ates, Ayten Dag, Ilayda Turkoglu, Ali Yagiz Ayla and Serdal Ugurlu, Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Inflammatory arthritis is a group of rheumatic diseases characterized by the inflammation of joints with systemic manifestations: psoriatic arthritis (PsA), rheumatoid arthritis (RA), and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].